<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5599">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04779983</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0100</org_study_id>
    <nct_id>NCT04779983</nct_id>
  </id_info>
  <brief_title>IL-6 as a Biomarker for Personalized Treatment of PR</brief_title>
  <acronym>REMISIX</acronym>
  <official_title>Evaluation of Professional Practices in the Prescription of Biological Treatments for RA Taking Into Account IL6 as a Biomarker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies have shown the relevance of the IL6 level before treatment or after 6 months,&#xD;
      as a predictive biomarker for the persistence of remission. The IL6 assay is now routinely&#xD;
      available using the instruments available at the Montpellier University Hospital and with&#xD;
      reagents provided by the ROCHE Laboratory. Moreover medical practices should incorporate this&#xD;
      parameter. However, relevant threshold shlould be defined before being able to integrate&#xD;
      biomarkers such as IL6 for monitoring bDMARDs in an algorithm.&#xD;
&#xD;
      The medical staff of Clinical Immunology Unit has decided to include the dosage of IL-6&#xD;
      during a routine biological assessment during patient visit to follow the new EULAR&#xD;
      recommendations . This measument will be perfom in addition to the CRP and biochemical&#xD;
      parameters on subjects with active RA or in remission upon the introduction of biological&#xD;
      treatments or JAKi or during remission after at least 6 months of treatment. From March to&#xD;
      July 2021, 200 patients will beenrolled and will benefit of this assessement. The&#xD;
      investigators will retrospectively define clinical correlations with serum IL6 levels in&#xD;
      order to define a threshold. In the second stage, a decisional algorithm based on the results&#xD;
      of this project will be create. This will allow an improvement of the medical practices&#xD;
      thanks to the integrationof of serum IL6 dosage as a standard during patients visits. The&#xD;
      IL-6 assay will be performed on the e801 module of the Cobas lines (Roche Diagnostics)&#xD;
      currently in place in the Biochemistry and Hormonology laboratory. The ElecsysÂ® IL-6 - Roche&#xD;
      Diagnostics test, high sensitivity, is an electrochemiluminescence immunoassay.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 18, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>serum IL6 levels.</measure>
    <time_frame>1 day</time_frame>
    <description>serum IL6 levels. From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The clinical correlations das 28 with the serum IL6 level</measure>
    <time_frame>1 day</time_frame>
    <description>The clinical correlations das 28 with the serum IL6 level</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with active RA (DAS28&gt; 3.6) who have failed methotrexate treatement and with a&#xD;
        standard medical care for which an indication for biotherapy is retained.&#xD;
&#xD;
        Subjects with remission of RA (DAS28&lt;2.6) for which a biotherapy delay (anti-TNF or&#xD;
        anti-IL6R or JAKi) is proposed.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  18 to 65 years old&#xD;
&#xD;
          -  patients with rheumatoid arthritis according to 2010 ACR/EULAR criteria who have one&#xD;
             of the following conditions:&#xD;
&#xD;
               -  Subjects with active RA (DAS28&gt; 3.6) who have failed methotrexate treatement and&#xD;
                  with a standard medical care for which an indication for biotherapy is retained&#xD;
                  or&#xD;
&#xD;
               -  Subjects with remission of RA (DAS28&lt;2.6) for which a biotherapy delay (anti-TNF&#xD;
                  or anti-IL6R or JAKi) is proposed.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Age under 18 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Jorgensen, PU PH</last_name>
    <role>Study Director</role>
    <affiliation>University Hospitals of Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rosanna Ferreira, MD</last_name>
    <phone>467 337902</phone>
    <phone_ext>33</phone_ext>
    <email>r-ferreira@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Jorgensen, PU PH</last_name>
    <phone>0467337231</phone>
    <phone_ext>33</phone_ext>
    <email>christian.jorgensen@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian Jorgensen, PU PH</last_name>
      <phone>046733723</phone>
      <phone_ext>33</phone_ext>
      <email>christian.jorgensen@inserm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IL-6</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

